Adaptive Biotechnologies raised its 2026 revenue guidance for its minimal residual disease (MRD) business after strong Q1 momentum in MRD testing volume. The Seattle-based company now expects full-year MRD revenue between $260 million and $270 million, with Q1 MRD revenue up 53% year over year to $67.1 million. Adaptive’s ClonoSeq MRD testing grew 54% year over year in Q1, with the company delivering a record number of tests and reporting blood-based ClonoSeq becoming nearly half of clinical testing. Adaptive also cited expansion in community-based testing and an average selling price increase during the quarter. The broader significance for the sector is the demonstrated commercial scaling of MRD platforms—particularly for hematologic malignancies—where consistent reimbursement and clinician adoption drive durable revenue. Adaptive’s guidance update indicates that both clinical volume and MRD-associated pharma milestones are supporting growth. Investors will likely focus on continued volume durability and whether the MRD test mix keeps improving as new indications and payer dynamics evolve.